General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling, Revocation and Suspension, and Forms FDA 356h & 2567

Forms and Documents

Forms and supporting documents for this ICR

Document	Type	Status	Availability
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Modified	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	New	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	New	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Removed	Repair queued
Form FDA 2567 Transmittals of Labels and Circulars	Form and Instruction	Removed	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Removed	Available
Form FDA 2567 Transmittals of Labels and Circulars	Form and Instruction	Removed	Available
Form FDA 2567 Transmittals of Labels and Circulars	Form and Instruction	Removed	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Removed	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Removed	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Removed	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Removed	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Removed	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Removed	Available
Form FDA 356h Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use	Form and Instruction	Removed	Available
0338SupportingStatementfinalout052910.doc	Supporting Statement A	Uploaded 2010-06-10	Available

IC Document Collections

Information collection document groups

IC ID	Collection	Type	Status	Form
5935	Sections 601, Forms FDA356h & 2567	Form and Instruction	Modified	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
193381	Section 601, recordkeeping, Forms FDA 356h & 2567	Form and Instruction	New	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
193380	Section 680, Forms FDA 356h & 2567	Form and Instruction	New	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179403	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed
179402	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179401	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed
179400	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed
179399	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed
179398	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Transmittals of Labels and Circulars
179397	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed
179396	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed
179395	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed
179394	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179394	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Transmittals of Labels and Circulars
179393	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Transmittals of Labels and Circulars
179392	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179391	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179390	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179389	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179388	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179387	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179386	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	Form and Instruction	Removed	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
179385	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed
179384	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed
179383	General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567		Removed

ICR Details

OMB Control No: 0910-0338	ICR Reference No: 201006-0910-001
Status: Historical Active	Previous ICR Reference No: 200703-0910-017
Agency/Subagency: HHS/FDA	Agency Tracking No:
Title: General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling, Revocation and Suspension, and Forms FDA 356h & 2567
Type of Information Collection: Extension without change of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 12/08/2010
Retrieve Notice of Action (NOA)	Date Received in OIRA: 06/24/2010
Terms of Clearance:

table that charts list comparision

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	12/31/2013	36 Months From Approved	10/31/2010
Responses	20,081	0	14,355
Time Burden (Hours)	341,697	0	335,808
Cost Burden (Dollars)	0	0	0

---

Abstract: The PHS Act and FDA regulations require manufacturers to submit a license application for review and approval prior to marketing a biological product in interstate commerce. Manufacturers must also submit to FDA supplements to an approved application, and advertising, and promotional labeling. There are also requirements regarding suspension and revocation of a license. The regulations also require each applicant of a licensed biological product to submit an annual progress report to FDA on the status of postmarketing studies for each approved biologics license application required by FDA or committed to by the applicant.

---

Authorizing Statute(s): US Code: 21 USC 356b Name of Law: FFDCA
   US Code: 42 USC 262 Name of Law: PHS Act
  

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	75 FR 4081	01/26/2010
30-day Notice:	Federal Register Citation:	Citation Date:
	75 FR 32790	06/09/2010
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 3

table that charts list of burden

IC Title	Form No.	Form Name
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 2567, FDA 356h	Transmittals of Labels and Circulars ,   Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 2567	Transmittals of Labels and Circulars
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 2567	Transmittals of Labels and Circulars
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
General Licensing Provisions: Biologics License App., Changes to an Approved App., Labeling, Revocation & Suspension, Postmarketing Studies Status Reports & Forms FDA356h & 2567
Section 601, recordkeeping, Forms FDA 356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
Section 680, Forms FDA 356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
Sections 601, Forms FDA356h & 2567	FDA 356h	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use

---

ICR Summary of Burden

table that charts list of burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	20,081	14,355	0	-14,327	20,053	0
Annual Time Burden (Hours)	341,697	335,808	0	-311,728	317,617	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: Yes

Burden Reduction Due to: Miscellaneous Actions

Short Statement: The change in burden hours is a result of updated data on the number of submissions received by FDA as a result of section 601.2 and 601.12(a), (c), (d), and (f).

---

Annual Cost to Federal Government: $17,573,130

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 06/24/2010

---